Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are likely to have a higher risk of cardiovascular events. Incorporating fibrosis measurements into routine clinical care for rheumatoid arthritis patients could identify individuals with highest risk and enable risk management strategies.
Read more here or reach out to our experts if you have any questions.
Related
Cardiovascular risk in elderly with obesity and liver fibrosis: Benefits of statins
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThere is a strong association between age, obesity, liver fibrosis and cardiovascular (CV) disease, particularly in the conte...
Insights from the CLEAR trial outcomes on MASLD and heart health
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascu...
Webinar – Time to event trial designs in ALS: How useful are they?
On NOVEMBER 26th, 2024, we organised the webinar: Time to event trial designs in ALS: How useful are they? During this webinar, our speakers Ruben van Eijk, Lotte Smets, Jordi van Unnik and host Lieza Exalto explored the following topics:A...
